Gut microbiota and allergic disease in children

Annals of Allergy, Asthma & Immunology

February  2016 Volume 116, Pages 99-105  CME Review


Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for ContinuingMedical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participationin the activity

Planning Committee Members:
Meghan B. Azad, PhD, (Author)
Anne K. Ellis, MD (Associate Editor)
Jonathan A. Bernstein, MD (CME Subcommittee)
Guha Krishnaswamy, MD (CME Subcommittee)
John J. Oppenheimer, MD (CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives


At the conclusion of this activity, participants should be able to:
Describe associations between infant gut microbiota and childhood allergic disease
Summarize research and published guidelines on pediatric allergy prevention and management strategies involving the gut microbiota

Additional information
Disclosure: 


M.H. Grayson has received research grants from Children’s Research Institute/Medical College of Wisconsin, Merck, National Institutes ofHealth (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, HRSA and National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor for AstraZeneca, GlaxoSmithKline, Meda, Mylan, and Sunovion; has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. A.K. Ellis has received research grants from Circassia, Sun Pharma Advanced Research, Merck, Novartis, Pfizer, and GlaxoSmithKline; has also been a consultant/advisor for Circassia, Merck, Novartis, and GlaxoSmithKline; and has been a speaker for Merck, Novartis, Takeda and AstraZeneca. J.A. Bernstein G. Krishnaswamy, M.B.Azad, A.B. Becker, S.L.Bridgman, A.L.Kozyrskyj, and J.A. Scott have nothing to disclose. Reviewers and Education/ Editorial staff have no relevant financial relationships to disclose. No unapproved/investigative use of a product/device is discussed.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
02/01/2016
Course expires: 
01/31/2018
Cost:
$0.00
Sarah L. Bridgman, BSc*; Anita L. Kozyrskyj, PhD*; James A. Scott, PhD; Allan B. Becker, MD; Meghan B. Azad, PhD

    Available Credit

    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Attendance

    Accreditation Period

    Course opens: 
    02/01/2016
    Course expires: 
    01/31/2018

    Price

    Cost:
    $0.00
    Please login or create an account to take this course.